Drugs / GLY-230
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT00544921 | Oct 2005 → Oct 2006 | diabetes mellitus | Glycadia | Completed | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT00544934 | Feb → Oct 2007 | diabetic kidney disease | Glycadia | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | GLY-230 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00544921 ↗ |
| Modality | Other / unclassified | “Anti-glycation Agent GLY-230” NCT00544934 ↗ |
| Route | Oral | “after taking it by mouth” NCT00544921 ↗ |